Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (VICTOR)

This study has been terminated.
(Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading study center Investigators; decision thus made to terminate.)
Information provided by (Responsible Party):
UCB Pharma Identifier:
First received: May 9, 2011
Last updated: January 21, 2014
Last verified: January 2014

The purpose of the trial is to investigate whether changes in lipids and hormonal parameters can be observed in blood when Carbamazepine treatment is replaced with Lacosamide treatment, while Levetiracetam treatment remains unchanged.

Condition Intervention Phase
Epilepsy, Partial
Drug: Lacosamide
Drug: Levetiracetam
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Levetiracetam

Resource links provided by NLM:

Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • change in serum sex hormone binding globulin (SHBG) from baseline to treatment period end [ Time Frame: from day 1 (baseline) to day 84 (treatment period end) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • change in sex hormone calculated free androgen index levels from baseline to treatment period end [ Time Frame: from day 1 (baseline) to day 84 (treatment period end) ] [ Designated as safety issue: No ]
    sex hormone calculated free androgen index level = 100x(testosterone/SHBG)

  • change in serum thyroid hormone free thyroxine level from baseline to treatment period end [ Time Frame: from day 1 (baseline) to day 84 (treatment period end) ] [ Designated as safety issue: No ]
  • change in total cholesterol level from baseline to treatment period end [ Time Frame: from day 1 (baseline) to day 84 (treatment period end) ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: July 2011
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lacosamide
commercial 50 mg (pinkish) and 100 mg (yellow) tablets
Drug: Lacosamide
4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
Other Name: Vimpat
Drug: Levetiracetam
Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
Other Name: Keppra


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male subject with diagnosis of Epilepsy with Partial-Onset Seizures
  • Subject only taking Levetiracetam in combination with Carbamazepine as adjunctive treatment for Epilepsy

Exclusion Criteria:

  • Subject is taking another Anti-Epileptic Drug (AED) than Carbamazepine (CBZ) and Levetiracetam (LEV)
  • Subject is taking lipid lowering agents
  • Subject is taking enzyme inducers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01375374

Innsbruck, Austria
Salzburg, Austria
Bielefeld, Germany
Bonn, Germany
Erlangen, Germany
Alcorcon, Spain
Santiago de Compostela, Spain
Sponsors and Collaborators
UCB Pharma
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

No publications provided

Responsible Party: UCB Pharma Identifier: NCT01375374     History of Changes
Other Study ID Numbers: SP0978, 2010-022534-84
Study First Received: May 9, 2011
Last Updated: January 21, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Austria: Austrian Medicines and Medical Devices Agency

Keywords provided by UCB Pharma:
Partial seizures
Hormone levels
Lipid levels

Additional relevant MeSH terms:
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Analgesics, Non-Narcotic
Antimanic Agents
Central Nervous System Agents
Central Nervous System Depressants
Nootropic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Tranquilizing Agents processed this record on November 24, 2014